BriaCell Therapeutics (TSE:BCT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BriaCell Therapeutics has dosed its first patient in a Phase 1/2 trial to test its innovative Bria-OTS™ immunotherapy for metastatic breast cancer, both as a standalone treatment and in combination with another cancer drug. This milestone highlights BriaCell’s commitment to advancing cancer treatments and improving patient outcomes through personalized and off-the-shelf therapies.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.